FGF10, under the drug name Repifermin, failed to prove efficacy in clinical trials for wound healing, mucositis, and ulcerative colitis (Freytes et al., 2004), though it had highly protective and therapeutic effects in animal models. This evidence concerns the gene FGF10 and mucositis.